Sweden-based Ascelia Pharma AB (STO: ACE) disclosed on July 3, 2026 that the US FDA issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for Orviglance (manganese chloride tetrahydrate), a novel oral manganese-based liver MRI contrast agent. The CRL arrived on the PDUFA date itself — July 3, 2026 — and means FDA approval will not be granted without further action by the company. The FDA cited the need for additional clinical data and product documentation, extending an approval timeline that had been expected to conclude this month.
The FDA informed Ascelia that it is currently unable to approve the Orviglance NDA in its present form, citing deficiencies in two areas: additional clinical data and product documentation. The CRL is notable given that the explicit reference to additional clinical data indicates that the FDA’s concerns extend beyond manufacturing or product quality alone, although the company has not disclosed the nature or scope of the requested data. This is the first regulatory action following FDA acceptance of the NDA for review in November 2025.
Ascelia submitted the Orviglance NDA in September 2025 following a nine-study clinical program, including the pivotal Phase III SPARKLE study, which demonstrated statistically significant improvement in visualization of focal liver lesions in patients with impaired kidney function, meeting the primary endpoint across all three independent readers (p<0.001). The NDA was accepted for standard 10-month review in November 2025, with a PDUFA date of July 3, 2026.
Ascelia had reported a positive pre-NDA meeting with the FDA in early 2025 that provided what the company characterized as clear and concrete guidance for the submission. The agency’s request for additional clinical data therefore represents a departure from the trajectory suggested by that pre-submission interaction.
Filing context
Orviglance is described as a potential first-in-class oral paramagnetic contrast agent, in which manganese ions — taken up by hepatocytes via calcium channels — accumulate in liver tissue and provide T1-weighted signal enhancement on MRI. The agent is designed specifically for patients with severe kidney impairment who cannot safely receive gadolinium-based contrast agents. The target population includes patients with liver cancer or metastases who require contrast-enhanced imaging for diagnosis and treatment planning. Ascelia has estimated a global annual addressable market of USD 800 million for this indication.
Orviglance holds FDA Orphan Drug Designation for use as a contrast agent for liver MRI in patients with severely impaired kidney function — a population at elevated risk for nephrogenic systemic fibrosis from gadolinium-based contrast agents, which carry regulatory warnings in this setting. No currently approved alternative oral manganese-based liver MRI contrast agent exists in the US market; gadolinium-based agents remain the standard of care despite their contraindication in severe renal impairment.
Ascelia stated it plans to request a Type A meeting with the FDA as soon as possible to understand the specific deficiencies in detail and identify an expedited path forward. CEO Magnus Corfitzen said the company remains confident in Orviglance and committed to making it available to patients. The company disclosed a cash runway into 2027 and said it will assess potential cost-saving initiatives. A resubmission timeline has not been indicated and will depend on the scope of additional clinical data required, which the Type A meeting is expected to clarify. If the FDA ultimately requires a new clinical study rather than additional analyses of existing data, approval could be delayed by years rather than months, although the scope of the agency’s request remains unknown.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team
Explore more at AllSci News: https://allsci.com/news/